Xenon Pharmaceuticals (XENE) Schedules Webcast for October 4th, 7AM EST to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time.

• A conference call and webcast with slides will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713.

The above listed dates and times are subject to change. When available, webcasts will be posted for replay following the event.

You May Also Be Interested In

• EU approves Arrowhead's plozasiran for rare triglyceride disorder
• People Inc. names new chief accounting officer as predecessor retires
• Murphy Oil announces oil discovery offshore Côte d'Ivoire